Oncopharmpod
New Chemo - Free Immunotherapy Options For NSCLC
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:16:29
- Mas informaciones
Informações:
Sinopsis
There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape. Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.
